The iconic rise of Sildenafil presented a significant opportunity for investors , but its patent has lapsed , creating a intricate landscape. Alternative versions have entered the market , cutting into profits and putting a strain on profit yields. While major pharmaceutical companies hold a presence in this field , the outlook looks clouded by int